Depression affects 280 million people worldwide. The mental illness has been proven to lead to changes in eating behavior. Researchers have discovered that although patients with depression generally ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

The first participants in an international clinical trial aimed at preventing Alzheimer's disease in young adults at high risk of the disease have been enrolled.

He also sardonically targeted co-host David Faber and said “Look I’m sure that when they discovered the cotton gin, and ...

Eli Lilly & Co. (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. Its products span oncology, ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

These growth stocks come from two very different industries. Eli Lilly is riding the GLP-1 drug wave, but there is much more ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...